［1］Wang Y, Leung FC. An evaluation of new criteria for CpG islands in the human genome as gene markers［J］. Bioinformatics, 2004, 20(7): 1170-1177.
［2］Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics［J］. Nat Rev Genet, 2008, 9(6): 465-476.
［3］Greaves M. In utero origins of childhood leukaemia［J］. Early Hum Dev, 2005, 81(1): 123-129.
［4］Conrad B, Antonarakis SE. Gene duplication: A drive for phenotypic diversity and cause of human disease［J］. Annu Rev Genomics Hum Genet, 2007, 8: 17-35.
［5］Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer［J］. Nat Rev Genet, 2006, 7(1): 21-33.
［6］Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Garate L, et al. Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome［J］. Leukemia, 2006, 20(8): 1445-1448.
［7］Davidsson J, Lilljebjorn H, Andersson A, Veerla S, Heldrup J, Behrendtz M, et al. The DNA methylome of pediatric acute lymphoblastic leukemia［J］. Hum Mol Genet, 2009, 18(21): 4054-4065.
［8］Flotho C, Paulun A, Batz C, Niemeyer CM. AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies［J］. Br J Haematol, 2007, 138(5): 644-650.
［9］Stam RW, den Boer ML, Passier M, Janka-Schaub GE, Sallan SE, Armstrong SA, et al. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia［J］. Leukemia, 2006, 20(2): 264-271.
［10］Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, et al. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options［J］. Blood, 2009, 114(27): 5490-5498.
［11］Sato H, Oka T, Shinnou Y, Kondo T, Washio K, Takano M, et al. Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma［J］. Am J Patholo, 2010, 176(1): 402-415.
［12］Gutierrez MI, Siraj AK, Bhargava M, Ozbek U, Banavali S, Chaudhary MA, et al. Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup［J］. Leukemia, 2003, 17(9): 1845-1850.
［13］RomanGomez J, JimenezVelasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, et al. Promoter hypermethylation of cancerrelated genes: a strong independent prognostic factor in acute lymphoblastic leukemia ［J］. Blood, 2004, 104(8): 2492-2498.
［14］Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia［J］. Leukemia, 2008, 22(8): 1529-1538.
［15］Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi HD, et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia［J］. Cancer Res, 2007, 67(6): 2617-2625.
［16］Figueroa ME, Reimers M, Thompson RF, Ye K, Li Y, Selzer RR, et al. An integrative genomic and epigenomic approach for the study of transcriptional regulation［J］. PLoS One, 2008, 3(3):e1882.
［17］Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, Xu D, et al. Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing［J］. Cancer Res, 2007, 67(18): 8511-8518.
［18］Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia［J］. Blood, 2010, 115(6): 1214-1225.
［19］Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JGCAM, Peters STCJM, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study［J］. Lancet Oncol, 2009, 10(2): 125134.
［20］Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JPJ. DNA methylation patterns at relapse in adult acute lymphocytic leukemia［J］. Clin Cancer Res, 2002, 8(6): 1897-1903.
［21］Wang H, Wang XQ, Xu XP, Lin GW. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome［J］. Leuk Res, 2010, 34(5): 598-604.
［22］Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Calasanz MJ, et al. CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia［J］. Clin Cancer Res, 2006, 12(16): 4845-4850.
［23］Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future［J］. Nat Rev Drug Discov, 2006, 5(1):e37-e50.
［24］Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy［J］. Nature, 2004, 429(6990): 457-463.
［25］Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies［J］. Leuk Lymphoma, 2007, 48(8): 1472-1481.
［26］Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et al. Preferential response of cancer cells to zebularine［J］. Cancer Cell, 2004, 6(2): 151-158.
［27］Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation"［J］. Science, 2003, 302(5648): 1153.
［28］Cortez CC, Jones PA. Chromatin, cancer and drug therapies［J］. Mutat Res, 2008, 647(1-2): 44-51.
［29］Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation［J］. Cancer Res, 2009, 69(10): 4277-4285.
［30］Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, Duan H, et al. Role for DNA methylation in the control of cell typespecific maspin expression［J］. Nat Genet, 2002, 31(2): 175-179.
［31］Hattori N, Nishino K, Ko YG, Hattori N, Ohgane J, Tanaka S, et al. Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells［J］. J Biol Chem, 2004, 279(17): 17063-17069.
